Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has announced that the first patient has been dosed in a Phase I clinical study for its candidate drug ISM5411. This follows the drug’s initial entry into clinical studies in Australia.
ISM5411 is an orally administered intestinal-restricted proton pump inhibitor developed to address inflammatory bowel disease (IBD), which encompasses both ulcerative colitis (UC) and Crohn’s disease (CD). Traditional IBD treatments have focused on inhibiting inflammation. ISM5411, however, utilizes a novel molecular framework and unique binding mode, developed with the aid of Insilico’s advanced generative chemistry engine, Chemistry42. The drug targets prolyl hydroxylase domain (PHD) to enhance the stability and transcriptional activity of hypoxia-inducible factor-1 alpha (HIF-1a), thereby promoting intestinal mucosal repair and exhibiting anti-inflammatory effects in the intestine.- Flcube.com
